41 completed, 16 terminated, 6 active not recruiting, 6 recruiting. 46 Phase 1, 42 Phase 2, 2 Early Phase 1, 2 Phase 3.
Follow entinostat: new trials by email Literature Review of entinostat trials Research Report on entinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer Entinostat, Oral Paclitaxel - Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 50 | 2026-04-01 | 2026-03-02 |
| A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer Entinostat, Fulvestrant - Locally Advanced or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2026-01-05 | 2025-11-19 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy entinostat, Fulvestrant, Anlotinib - Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 118 | 2025-11-24 | 2026-01-09 |
| Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer entinostat, Dalpiciclib, Letrozole - Breast Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 60 | 2025-09-12 | 2026-04-02 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities Entinostat, VAC/VTC chemotherapy - Soft Tissue Sarcoma | Phase 1 | Recruiting | Beijing Tongren Hospital | 16 | 2025-03-15 | 2026-10-22 |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-02 | 2024-08-05 | |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Brachyury-TRICOM, Entinostat, M7824 - Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2021-05-04 | 2022-01-11 |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Atezolizumab, Carboplatin, Entinostat - Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 3 | 2021-04-27 | 2025-10-03 |
| A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma Entinostat, FOLFOX regimen - Pancreas Cancer | Phase 1 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2021-01-01 | 2021-01-15 | |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Pembrolizumab, Entinostat, Procedure/Surgery - Bladder Cancer | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-09-23 | 2026-10-23 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer Entinostat, Enzalutamide - Prostate Adenocarcinoma | Phase 1 | Terminated | George Washington University | 6 | 2019-05-01 | 2021-08-02 |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma Entinostat, Pembrolizumab - Melanoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 11 | 2019-03-22 | 2024-01-10 |
| A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy Entinostat, Capecitabine - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Completed | University of Virginia | 13 | 2019-01-29 | 2022-11-01 |
Showing 20 of 77. Sign in to see all of them.
Breast Neoplasms (25) · Carcinoma, Non-Small-Cell Lung (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myeloid, Acute (5) · Lung Neoplasms (5) · Neoplasms (5) · Pancreatic Neoplasms (5) · Breast Diseases (4) · Carcinoma, Renal Cell (4) · Leukemia, Myelomonocytic, Chronic (4) · Melanoma (4) · Triple Negative Breast Neoplasms (4) · Bronchial Neoplasms (3) · Colonic Neoplasms (3) · Congenital Abnormalities (3)
National Cancer Institute (NCI) (26) · Syndax Pharmaceuticals (18) · Roberto Pili (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · UNC Lineberger Comprehensive Cancer Center (3) · Abramson Cancer Center at Penn Medicine (2) · Kyowa Kirin Co., Ltd. (2) · Taizhou EOC Pharma Co., Ltd. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Antonio Fojo (1) · Bayer (1) · Beijing Tongren Hospital (1) · George Washington University (1) · Hebei Medical University Fourth Hospital (1) · Hoffmann-La Roche (1)
United States (60) · China (8) · Japan (2) · Sweden (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Hungary (1) · Ireland (1) · Israel (1) · Netherlands (1)
Michael Meyers, MD, PhD (4) · Denise Yardley, MD (2) · Laura Sterling, MD (2) · Patricia M LoRusso (2) · Roberto Pili, MD (2) · Roisin M Connolly (2) · Alex Adjei (1) · Alex Adjei, MD (1) · Alison Moskowitz, MD (1) · Amer M Zeidan (1) · Andrew Baildam, MD (1) · Andrew Bukowinski (1) · Antonio Fojo, MD, PhD (1) · B. Smith (1)
PMID 24583822, PMID 26577691, PMID 39863139, PMID 19546476, PMID 19652201, PMID 22586682, PMID 23650416, PMID 27151994, PMID 31046743, PMID 32503469, PMID 33203644, PMID 34196874, PMID 34357781, PMID 34453044, PMID 34563945, PMID 34819039, PMID 35552447, PMID 36398439, PMID 37250148, PMID 37377898, PMID 37555284, PMID 38036712, PMID 38356965, PMID 38886159, PMID 39532835
U01CA070095 (8), P30CA006973 (7), UM1CA186689 (4), UM1CA186691 (4), N01CM00038 (2), N01CM00099 (2), U10CA021115 (2), U10CA180820 (2), UM1CA186717 (2), 2004 (1), 2009 (1), 2017 (1), 2018 (1), N01CM62205 (1), P01CA247886 (1)